Literature DB >> 6608352

The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population.

S M van der Linden, H A Valkenburg, B M de Jongh, A Cats.   

Abstract

The present study was performed on 61 HLA-B27 positive first-degree relatives and 40 HLA-B27 negative relatives of 20 HLA-B27 positive probands with ankylosing spondylitis (AS). Of 24 HLA-B27 positive relatives 45 years or older, 21% had AS and 38% sacroiliitis. The HLA-B27 negative relatives did not have features of either disease. In the population study of 2,957 individuals 45 years or older, we found 5 cases of HLA-B27 positive sacroiliitis (according to the New York criteria) and 3 of these fulfilled the New York criteria for diagnosis of AS. In 2 of these 3 individuals, the diagnosis was made on clinical grounds. The phenotype frequency of HLA-B27 in this population is 7.8%, or about 230 HLA-B27 positive individuals in this population sample. Since AS was found in only 3 individuals, 1.3% of the HLA-B27 positive individuals in the population at large have AS; therefore, our data show that among individuals 45 years or older, 21% of HLA-B27 positive relatives of HLA-B27 positive AS patients have AS as compared with 1.3% of the HLA-B27 positive individuals in the population at large. Thus, the risk for AS is 16 times greater in the HLA-B27 positive relatives compared with HLA-B27 positive individuals in the population at large. The discriminatory value of the New York criterion of history of pain or the presence of pain at the dorsolumbar junction or in the lumbar spine was analyzed in the population and family studies and was found to be too nonspecific.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6608352     DOI: 10.1002/art.1780270301

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  119 in total

Review 1.  Unmet Needs in Axial Spondyloarthritis.

Authors:  Ennio Lubrano; Antonia De Socio; Fabio Massimo Perrotta
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

2.  The association between TNF-alpha promoter polymorphisms and ankylosing spondylitis: a meta-analysis.

Authors:  Bing Li; Pei Wang; Hui Li
Journal:  Clin Rheumatol       Date:  2010-06-11       Impact factor: 2.980

Review 3.  International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

Authors:  J Braun; T Pham; J Sieper; J Davis; Sj van der Linden; M Dougados; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

4.  How does HLA-B27 confer susceptibility to inflammatory arthritis?

Authors:  J S Gaston
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

5.  Pain thresholds in rheumatic diseases.

Authors:  A S Rigby
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

6.  [Early axial spondyloarthritis. Diagnostic approach and screening].

Authors:  D Poddubnyy; M Rudwaleit; J Sieper
Journal:  Z Rheumatol       Date:  2012-01       Impact factor: 1.372

7.  Withdrawal from labour force due to work disability in patients with ankylosing spondylitis.

Authors:  A Boonen; A Chorus; H Miedema; D van der Heijde; R Landewé; H Schouten; H van der Tempel; S van der Linden
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

8.  Polymorphism of tumour necrosis factor-alpha (TNF-alpha) at position -308 in relation to ankylosing spondylitis.

Authors:  G M Verjans; B M Brinkman; C E Van Doornik; A Kijlstra; C L Verweij
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

9.  [Spondylarthritides].

Authors:  J Braun; J Sieper
Journal:  Z Rheumatol       Date:  2006-11       Impact factor: 1.372

Review 10.  Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics.

Authors:  Heiner Appel; Joachim Sieper
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.